NCT04167761View on ClinicalTrials.gov

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Cardiovascular DiseasesAtherosclerosisType 2 DiabetesInsulin Resistance
Interventions
DRUG

Ertugliflozin

Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Stanford University

OTHER

NCT04167761 - Ertugliflozin: Cardioprotective Effects on Epicardial Fat | Biotech Hunter | Biotech Hunter